VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Admitted to any ICU and receiving invasive         │ Admitted to any ICU and receiving invasive         │     100 │
│ mechanical ventilation                             │ mechanical ventilation                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients at potential increased risk of iatrogenic │ Patients at potential increased risk of iatrogenic │     100 │
│ probiotic infection (see Section 2.6 for detailed  │ probiotic infection (see Section 2.6 for detailed  │         │
│ explanation) including specific immunocompromised  │ explanation) including specific immunocompromised  │         │
│ populations (HIV \<200 CD4 cells/μL, those         │ populations (HIV <200 CD4 cells/µL, those          │         │
│ receiving chronic immunosuppressive medications    │ receiving chronic immunosuppressive medications    │         │
│ (e.g., azathioprine, cyclosporine,                 │ (e.g., azathioprine, cyclosporine,                 │         │
│ cyclophosphamide, tacrolimus, methotrexate,        │ cyclophosphamide, tacrolimus, methotrexate,        │         │
│ mycofenolate, Anti-IL2), previous transplantation  │ mycofenolate, Anti-IL2), previous transplantation  │         │
│ (including stem cell) at any time, malignancy      │ (including stem cell) at any time, malignancy      │         │
│ requiring chemotherapy in the last 3 months,       │ requiring chemotherapy in the last 3 months,       │         │
│ neutropenia \[absolute neutrophil count \< 500\]). │ neutropenia [absolute neutrophil count < 500]).    │         │
│ However, patients receiving corticosteroids        │ However, patients receiving corticosteroids        │         │
│ previously or presently or projected to receive    │ previously or presently or projected to receive    │         │
│ corticosteroids are not excluded                   │ corticosteroids are not excluded                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients at risk for endovascular infection        │ Patients at risk for endovascular infection        │     100 │
│ (previously documented rheumatic heart disease,    │ (previously documented rheumatic heart disease,    │         │
│ congenital valve disease, surgically repaired      │ congenital valve disease, surgically repaired      │         │
│ congenital heart disease, unrepaired cyanotic      │ congenital heart disease, unrepaired cyanotic      │         │
│ congenital heart disease, any intracardiac repair  │ congenital heart disease, any intracardiac repair  │         │
│ with prosthetic material \[mechanical or bio-      │ with prosthetic material [mechanical or bio-       │         │
│ prosthetic cardiac valves\], previous or current   │ prosthetic cardiac valves], previous or current    │         │
│ endocarditis, permanent endovascular devices       │ endocarditis, permanent endovascular devices       │         │
│ (e.g., endovascular grafts \[e.g., aortic aneurysm │ (e.g., endovascular grafts [e.g., aortic aneurysm  │         │
│ repair, stents involving large arteries such as    │ repair, stents involving large arteries such as    │         │
│ aorta, femorals and carotids\], inferior vena cava │ aorta, femorals and carotids], inferior vena cava  │         │
│ filters, dialysis vascular grafts), tunnelled (not │ filters, dialysis vascular grafts), tunnelled (not │         │
│ short-term) hemodialysis catheters, pacemakers or  │ short-term) hemodialysis catheters, pacemakers or  │         │
│ defibrillators. Patients with temporary central    │ defibrillators. Patients with temporary central    │         │
│ venous catheters, central venous dialysis          │ venous catheters, central venous dialysis          │         │
│ catheters or peripherally inserted central         │ catheters or peripherally inserted central         │         │
│ catheters (PICCs) are not excluded and patients    │ catheters (PICCs) are not excluded and patients    │         │
│ with coronary artery stents, coronary artery       │ with coronary artery stents, coronary artery       │         │
│ bypass grafts (CABG) or neurovascular coils are    │ bypass grafts (CABG) or neurovascular coils are    │         │
│ not excluded; patients with mitral valve prolapse  │ not excluded; patients with mitral valve prolapse  │         │
│ or bicuspid aortic valve are not excluded          │ or bicuspid aortic valve are not excluded          │         │
│ providing they have no other exclusion criteria    │ providing they have no other exclusion criteria    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with percutaneous gastric or jejunal      │ Patients with percutaneous gastric or jejunal      │     100 │
│ feeding tubes already in situ as per Health Canada │ feeding tubes already in situ as per Health Canada │         │
│ guidance                                           │ guidance                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Strict contraindication or inability to receive    │ Strict contraindication or inability to receive    │     100 │
│ enteral medications                                │ enteral medications                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Intent to withdraw advanced life support as per    │ Intent to withdraw advanced life support as per    │     100 │
│ the ICU physician                                  │ the ICU physician                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previous enrolment in this or current enrolment in │ Previous enrolment in this or current enrolment in │     100 │
│ a potentially confounding tria                     │ a potentially confounding tria                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Adults ≥ 18 years of age                           │ Adults = 18 years of age                           │      96 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Anticipated ventilation of ≥72 hours at the time   │ Anticipated ventilation of =72 hours at the time   │      99 │
│ of screening, as per the ICU physician             │ of screening, as per the ICU physician             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Invasively mechanically ventilated \>72 hours at   │ Invasively mechanically ventilated >72 hours at    │      99 │
│ the time of screening                              │ the time of screening                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with a primary diagnosis of severe acute  │ Patients with a primary diagnosis of severe acute  │      99 │
│ pancreatitis, without reference to a Ranson score  │ pancreatitis, without reference to a Ranson score  │         │
│ \[Ranson 1974\]). However, patients with mild or   │ [Ranson 1974]). However, patients with mild or     │         │
│ moderate pancreatitis are not excluded             │ moderate pancreatitis are not excluded             │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤══════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria            │   Score │
╞═══════════════════════════════════╪══════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Adults = 18 years of age │      39 │
╘═══════════════════════════════════╧══════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 94.33333333333333
OverAll Ratio: 96.66666666666666
